Skip to content
Screener

Design Therapeutics, Inc. DSGN Q4 2025 Annual earnings

Reported March 9, 2026 · Before market open

Revenue-
EPS-$0.27Beat by $0.11
EPS estimate-$0.38

Next report

Nov 4, 2026 (in 2 months)
EPS estimate-$0.38

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$18.2M-8.8%
Net income-$16.0M-17.2%
EPS (diluted)-$0.27-12.5%

Balance sheet

See full
Cash & equivalents$16.9M-25.3%
Total debt$1.5M-34.2%
Total equity$212.5M-12.2%
Total assets$226.2M-10.3%

Cash flow

See full
Operating cash flow-$12.0M-21.4%
CapEx$34.0K—
Free cash flow-$12.0M-21.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$534.32M+52.9%
Enterprise value$519M+57.7%

Returns & leverage

See full
Return on equity-30.7%+47.9pp
Debt / equity0×0.0×
Current ratio17.1×-12.2×

FAQ

When did Design Therapeutics, Inc. report Q4 2025 earnings?
Design Therapeutics, Inc. (DSGN) reported Q4 2025 earnings on March 9, 2026 before market open.
What were Design Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Design Therapeutics, Inc. reported revenue of - and eps of $-0.27 for Q4 2025.
Did Design Therapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.38 by $0.11.
How did Design Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 12.5% from $-0.24.
Where can I find Design Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-098474) and the 10-K periodic report (0001193125-26-098491) directly on SEC EDGAR. The filing index links above go to sec.gov.